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Dear Editor,
Inflammatory bowel diseases (IBDs) such as Crohn’s disease 
(CD) and ulcerative colitis (UC) are chronic relapsing inflamma-
tory disorders of the intestine that are characterized by abdomi-
nal pain and diarrhea [1, 2]. The incidence of IBD is increasing 
globally and has also increased in Korea recently [2, 3]. Although 
the etiology is unknown, the relationship between the colonic mi-
crobiota and IBD has been indicated as a possible contributor. 
Fusobacterium varium and F. nucleatum have emerged as com-
pelling candidates responsible for IBD exacerbation [4, 5]. The 
colonization by these strains is possibly a useful biomarker for di-
agnosing gastrointestinal diseases [5]. We aimed to determine 
the prevalence of Fusobacterium spp. from colonic biopsies of 
IBD patients in Korea.
All 54 patients fulfilling the diagnostic criteria for IBD includ-
ing 26 of CD, 25 of UC, or 3 of Behcet’s disease (BD), at Han-
yang University Guri Hospital between June 2014 and June 
2015 were included in this study. Among them, 41 (76%) were 
male. The patient ages ranged from 14 to 75 yr (median: 31 yr). 
The Institutional Review Board of Hanyang University Guri Hos-
pital approved this study. Biopsy material was obtained from pa-
tients undergoing colonoscopy for assessment of IBD status or 
for confirmation of gastrointestinal disease. Tissues were put 
into pre-reduced phosphate-buffered saline and immediately 
transported to the laboratory for bacterial culture. The speci-
mens were ground, inoculated on crystal violet erythromycin 
(CVE) agar supplemented with tryptophan, and incubated at 
37°C for 48 hr in an anaerobic jar [6]. All isolates showing a dif-
ferent colony morphology were identified by 16S rRNA gene se-
quencing by using PCR predicted to yield a product of 1,300 bp 
[7]. The PCR conditions were as follows: 95°C for 5 min; 30 cy-
cles at 95°C for 30 sec, 55°C for 30 sec, and 72°C for 1 min; 
and a final 10-min step at 72°C. The sequencing of the amplifi-
cation products were performed in a commercial facility (Mac-
rogen, Seoul, Korea). The sequencing analysis was completed 
using the GenBank and EzTaxon databases. Some strains were 
identified using the MicroScan WalkAway automated system 
(Dade Behring, West Sacramento, CA, USA) and the Vitek MS 
system (bioMérieux, Marcy l’Etoile, France). Ten Fusobacterium 
isolates were recovered from nine of the 54 patients as follows: 
six F. mortiferum, two F. varium, and one F. nucleatum and F. 
mortiferum (Table 1). 
Clinically, the most important Fusobacterium species are F. 
nucleatum and F. necrophorum, but F. ulcerans and the F. mor-
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tiferum–F. varium group have occasionally been isolated from 
human. Ohkusa et al. [4] suggested that F. varium might be one 
of the elusive pathogenic factors in UC. In addition, Strauss et al. 
[5] reported that an F. nucleatum strain isolated from IBD tis-
sues was more invasive than strains isolated from normal tis-
sues. A correlation between UC and colonization with F. varium 
has also been noted in a cohort of Japanese patients [4]. F. nu-
cleatum has been linked to colorectal cancer as well as IBD, 
which has been recognized as a risk factor of colorectal cancer 
[8]. Fusobacterium spp. were isolated from 63.6% and 53.1% 
of IBD patients in Canada and Japan, where F. nucleatum was 
more prevalent in the Canadian patients (43%) than in the Japa-
nese patients (4%) [5, 9]. The prevalence of Fusobacterium in 
our study cohort was 17%, which was lower than that in Canada 
and Japan. 
There were limitations of our study that could have affected 
the low recovery rate. First, whereas we allowed only two days of 
incubation time for anaerobic culture, Strauss et al. [5] allowed 
five days. Hence, it was possible that some Fusobacterium spp. 
were lost owing to early termination of the incubation. Further-
more, with a longer incubation time, the anaerobic chamber 
may be more optimal than the anaerobic jar that we used. Sec-
ond, for the specific recovery of Fusobacterium spp. from clini-
cal specimens, the josamycin, vancomycin, and norfloxacin in 
JVN agar are better than the CVE agar that we used [10]. Fur-
ther studies are necessary because of our small sample size 
and the absence of strains isolated from healthy controls. Al-
though it is not possible to draw any strong conclusions from 
this small data subset, it is likely that there are differences of 
isolated species according to the country of origin, supporting 
the notion that no single bacterial species is a biomarker of IBD.
In conclusion, this study is the first attempt to assess the 
prevalence of Fusobacterium spp. in colonic tissues of IBD pa-
tients in Korea, revealing that only 17% of the patients carried 
species of this genus.
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